RASSF1A Gene Methylation is Associated with Nasopharyngeal Carcinoma Risk in Chinese

Wu, Kun; Xu, Xiao-Ning; Chen, Yu; Pu, Xiaolin; Wang, Bo-Yuan; Tang, Xiaodan

doi:10.7314/apjcp.2015.16.6.2283

Cited by 8 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the patterns of TSG promoters’ methylation have been studied, and are reported to act as the potential epigenetic biomarkers for NPC. 9,12 RASSF1A (RAS-association domain family 1 isoform A), located at 3p21.31, belongs to the family of RAS effectors, It is a well-described tumor suppressor gene, which encodes the scaffold protein member of the C-terminal RASSF family. 16 It functions as the signaling protein that plays important roles in cell signal transduction by regulating the complex signal networks, including ERK, Hippo, apoptotic, and p53 death receptor signal pathways.…”

Section: Introductionmentioning

confidence: 99%

Hypermethylation of the RASSF1A gene promoter as the tumor DNA marker for nasopharyngeal carcinoma

et al. 2021

View full text Add to dashboard Cite

Background RASSF1A is a tumor suppressor gene. The methylation of RASSF1A has been reported to be associated with nasopharyngeal tumorigenesis. However, the heterogeneity was high among different studies. A meta-analysis was performed to evaluate the value of RASSF1A methylation for the diagnosis and early screening of nasopharyngeal carcinoma. Methods Relevant articles were identified by searching the MEDLINE database. Frequency and odds ratio (OR) were applied to estimate the effect of CDH-1 methylation based on random-/fixed-effect models. The meta-analysis was performed by using MedCalc® software. Subgroup analyses were performed by test method, ethnicity, and source of nasopharyngeal carcinoma samples to determine likely sources of heterogeneity. Results A total of 17 studies, including 1688 samples (1165 nasopharyngeal carcinoma samples, and 523 from non-cancerous samples) were used for the meta-analysis. The overall frequencies of RASSF1A methylation were 59.68% and 2.65% in case-group and control-group, respectively. By removing the poor relative studies, the heterogeneity was not observed among the studies included. The association between RASSF1A gene methylation and the risk of nasopharyngeal carcinoma was also confirmed by calculating the OR value of 30.32 (95%CI = 18.22–50.47) in the fixed-effect model (Q = 16.41, p = 0.36,I 2 = 8.62, 95% CI = 0.00–45.27). Additionally, the significant association was also found between the methylation of the RASSF1A gene and the subgroups. Conclusions This is the first meta-analysis that has provided scientific evidence that the methylation of RASSF1A is the potential diagnosis, prognosis, and early screening biomarker for nasopharyngeal carcinoma.

show abstract

Section: Introductionmentioning

confidence: 99%

Hypermethylation of the RASSF1A gene promoter as the tumor DNA marker for nasopharyngeal carcinoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A high frequency of RASSF1A inactivation or down-regulation by gene promoter hypermethylation has been observed in NPC 22,23 . RASSF1A impairs cell proliferation in vitro and in vivo 24 , and methylation of its promoter has been linked to unfavorable prognosis in patients with NPC 25,26 . Restoration of RASSF1A expression is difficult due to technical issues and is accompanied by unpredictable complications; thus, determining its downstream effectors is necessary.…”

Section: Introductionmentioning

confidence: 99%

RASSF1A inhibits PDGFB-driven malignant phenotypes of nasopharyngeal carcinoma cells in a YAP1-dependent manner

et al. 2020

View full text Add to dashboard Cite

Nasopharyngeal carcinoma (NPC) is a highly aggressive tumor characterized by distant metastasis. Deletion or down-regulation of the tumor suppressor protein ras-association domain family protein1 isoform A (RASSF1A) has been confirmed to be a key event in NPC progression; however, little is known about the effects or underlying mechanism of RASSF1A on the malignant phenotype. In the present study, we observed that RASSF1A expression inhibited the malignant phenotypes of NPC cells. Stable silencing of RASSF1A in NPC cell lines induced self-renewal properties and tumorigenicity in vivo/in vitro and the acquisition of an invasive phenotype in vitro. Mechanistically, RASSF1A inactivated Yes-associated Protein 1 (YAP1), a transcriptional coactivator, through actin remodeling, which further contributed to Platelet Derived Growth Factor Subunit B (PDGFB) transcription inhibition. Treatment with ectopic PDGFB partially increased the malignancy of NPC cells with transient knockdown of YAP1. Collectively, these findings suggest that RASSF1A inhibits malignant phenotypes by repressing PDGFB expression in a YAP1-dependent manner. PDGFB may serve as a potential interest of therapeutic regulators in patients with metastatic NPC.

show abstract

“…Many TSGs have been recorded to be involved in the critical cancer-related cellular pathways. Thus, the patterns of TSG promoters' methylation have been studied, and reported to be acted as the potential epigenetic biomarkers for NPC [9,12]. RASSF1A (RAS-association domain family 1 isoform A), located 3p21.31, belonged to the family of RAS effectors, is a tumor suppressor gene coding protein.…”

Section: Introductionmentioning

confidence: 99%

Could the methylation of RASSF1A be the potential epigenetic biomarker for nasopharyngeal carcinoma? – Systematic review and meta-analysis

Lao

Thieu

Nguyen

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background: RASSF1A is a tumor suppressor gene. The methylation of RASSF1A has been reported to be associated with the nasopharyngeal tumorigenesis. Aiming to evaluate the association between the RASSF1A gene methylation and nasopharyngeal cancer, and its correlation could be used as an epigenetic biomarker for NPC cancer risk based on meta-analysis.Methods: Relevant articles were identiﬁed by searching MEDLINE database. The frequency and Odds ratio (OR) were applied to estimate the effect of CDH-1 methylation based on random-/fix-effects models. Furthermore, subgroup analyses were performed by test-method, ethnicity, source of NPC samples.Results: Total of 16 studies, included 1,766 samples: 1,178 samples from NPC samples, and 588 samples from non-cancerous samples, were enrolled in the meta-analysis. The overall frequency of RASSF1A methylation were 55.98% and 1.70% in case-group and control-group, respectively. By removing the poor relative studies, the heterogeneity was not observed among included studies. The association between the RASSF1A gene methylation and risk of NPC was also confirmed by calculating OR value of 51.43 (95%OR = 28.12-94.08) in fix-effects model (Q = 10.63, p = 0.99, I2 = 0.00, 95% CI = 0.00-0.00). Additionally, the significant association was also found between the methylation of RASSF1A gene and subgroups.Conclusion: this was the first meta-analysis provided scientific evidences to suggest the RASSF1A methylation was the potential biomarker for risk of NPC.

show abstract

RASSF1A Gene Methylation is Associated with Nasopharyngeal Carcinoma Risk in Chinese

Cited by 8 publications

References 21 publications

Hypermethylation of the RASSF1A gene promoter as the tumor DNA marker for nasopharyngeal carcinoma

Hypermethylation of the RASSF1A gene promoter as the tumor DNA marker for nasopharyngeal carcinoma

RASSF1A inhibits PDGFB-driven malignant phenotypes of nasopharyngeal carcinoma cells in a YAP1-dependent manner

Could the methylation of RASSF1A be the potential epigenetic biomarker for nasopharyngeal carcinoma? – Systematic review and meta-analysis

Contact Info

Product

Resources

About